2 completed, 1 active not recruiting, 1 not yet recruiting, 1 no longer available. 2 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Thyroid cancer, medullary: new trials by email Literature Review of Thyroid cancer, medullary trials Research Report on Thyroid cancer, medullary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2026-01-01 | 2025-11-28 |
| Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer 18F-PSMA-1007 - Medullary Thyroid Cancer, Medullary Thyroid Carcinoma | Not applicable | Completed | University Medical Center Groningen | 8 | 2022-08-19 | 2025-06-24 |
| 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer 177Lu-PP-F11N, Sacuitril - Thyroid Cancer, Medullary | Early Phase 1 | Completed | University Hospital, Basel, Switzerland | 8 | 2018-12-13 | 2022-02-10 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. 177Lu-PP-F11N - Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2 | Phase 1 | Active not recruiting | University Hospital, Basel, Switzerland | 24 | 2015-04-01 | 2026-05-01 |
| 18F-FDOPA PET in Neuroendocrine Tumours [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) - Thyroid Cancer, Medullary, Carcinoid Tumor | No longer available | British Columbia Cancer Agency | 2023-02-21 |
Carcinoma, Medullary (4) · Thyroid Neoplasms (2) · Adenocarcinoma, Follicular (1) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Gallbladder Neoplasms (1) · Insulinoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1) · Paraganglioma (1) · Pheochromocytoma (1)
Adenocarcinoma (6) · Carcinoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (5) · Carcinoma, Neuroendocrine (4) · Neoplasms by Site (4) · Neoplasms, Ductal, Lobular, and Medullary (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Digestive System Diseases (2)
3-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid (1) · Sorafenib (1) · cabozantinib (1) · fluorodopa F 18 (1) · lenvatinib (1) · sacubitril and valsartan sodium hydrate drug combination (1) · vandetanib (1)
University Hospital, Basel, Switzerland (2) · AccSalus Biosciences, Inc. (1) · British Columbia Cancer Agency (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · University Medical Center Groningen (1)
Switzerland (2) · Canada (1) · Netherlands (1) · United States (1)
Christof Rottenburger, Dr. med. (2) · Christine H. Chung, M.D. (1) · Damian Wild, PhD Dr (1) · Damian Wild, Prof Dr Dr (1)
2018 (1)